Norovirus vaccine formulations
AssigneeTakeda Vaccines, Inc.
InventorsCharles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
Life of this patent
Estimating the term…
Abstract
The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
Claims41
An immunogenic composition comprising at least one Norovirus antigen and an effective amount of at least one adjuvant, wherein the adjuvant is a toll-like receptor (TLR) agonist that is not a bacterial exotoxin, wherein said antigen comprises Norovirus virus-like particles (VLPs), and wherein the composition is formulated as a stable dry powder, wherein the percent aggregation of VLPs in the composition remains constant or decreases when measured over a twelve month period.
A composition comprising at least two Norovirus antigens, an effective amount of at least one adjuvant that is a TLR agonist that is not a bacterial exotoxin, and a mucoadhesive, wherein at least one of said Norovirus antigens comprises Norovirus virus-like particles (VLPs) produced from a genogroup I viral strain, and wherein at least one of said Norovirus antigens comprises Norovirus VLPs produced from a genogroup II viral strain, and wherein the composition is formulated as a stable dry powder.
Dependencies are inferred from the claim text.